Is Astria Therapeutics, Inc. (ATXS) a Buy, Sell, or Hold?
Astria Therapeutics, Inc.
NASDAQ:ATXS
$12.58 USD
$0 (0.0%)
- Volume
- 3.06M
- Average Volume
- 1.07M
- Market Capitalization
- $718.13M
- P/E Ratio
- -7.40
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $13.29
- Year Low
- $3.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jill C. Milne |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ATXS |
| CUSIP | 04635X102 |
| CIK | 0001454789 |
| Web | https://www.astriatx.com |
| Phone | 617 349 1971 |
| Currency | USD |
| Employees | 78 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.78 |
| Quick Ratio | 10.78 |
| Cash Ratio | 4.09 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 1017.18 |
| Cash Flow | -1.78 |
| Price / Cash Flow | -6.97 |
| Price / Book | 3.13 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $26.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -37.10% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.68 |
| Trailing P/E Ratio | -7.40 |
| PEG Ratio | 0.90 |
| P/E Growth | 0.90 |
| Net Income | $-94.26M |
| Net Margin | -13938.24% |
| Pretax Margin | -13938.24% |
| Return on Equity | -37.70% |
| Return on Assets | -36.20% |
Financials Score
| AltmanZ Score | 6.69 |
| Piotroski Score | 3.00 |
| Working Capital | 230.03M |
| Total Assets | 271.87M |
| Ebit | -124.03M |
| Market Cap | 718.13M |
| Total Liabilities | 38.61M |
Poll Results
About Astria Therapeutics, Inc. (NASDAQ:ATXS) Stock
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc. ...
Frequently Asked Questions
-
What is the current Astria Therapeutics, Inc. (ATXS) stock price?
-
Astria Therapeutics, Inc.(NASDAQ:ATXS) stock price is $12.58 in the last trading session. During the trading session, ATXS stock reached the peak price of $13.29 while $3.555 was the lowest point it dropped to. The percentage change in ATXS stock occurred in the recent session was 0.0% while the dollar amount for the price change in ATXS stock was $0.
-
ATXS's industry and sector of operation?
-
The NASDAQ listed ATXS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATXS?
-
Christopher J. Morabito | Chief Medical Officer
Benjamin S. Harshbarger | Chief Legal Officer
John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations
Andrea L. Matthews | Chief Business Officer
Jill C. Milne | Co-Founder, Chief Executive Officer, President & Director -
How many employees does ATXS have?
-
Number of ATXS employees currently stands at 78. ATXS operates from 100 High Street, Boston, MA 02110, US.
-
Link for ATXS official website?
-
Official Website of ATXS is: https://www.astriatx.com
-
How do I contact ATXS?
-
ATXS could be contacted at phone #617 349 1971 and can also be accessed through its website. ATXS operates from 100 High Street, Boston, MA 02110, US.
-
How many shares of ATXS are traded daily?
-
The average number of ATXS shares traded daily for last 3 months was 1.07M.
-
What is the market cap of ATXS currently?
-
The market value of ATXS currently stands at $718.13M with its latest stock price at $12.58